ArticleClinical journal of gastroenterology2026
Pancreatic juice CEA during SPACE for pancreatic duct stenosis: diagnostic and exploratory risk stratification value.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated whether pancreatic juice carcinoembryonic antigen (PJ-CEA) measurement during serial pancreatic juice aspiration cytologic examination (SPACE) enhanced diagnostic accuracy and was associated with subsequent pancreatic cancer (PC) diagnosis, especially in cytology-negative patients.
methodsWe retrospectively analyzed 206 patients undergoing both SPACE and PJ-CEA testing. Patients were classified into definitive diagnosis (intraductal papillary mucinous neoplasm [IPMN], non-malignant controls, or PC) and non-definitive diagnosis groups. Because PJ-CEA may be elevated in IPMN regardless of malignant potential, the cutoff for distinguishing PC from non-malignant controls was determined by ROC analysis after excluding IPMN cases from the definitive diagnosis group. Diagnostic performance was compared for SPACE alone, PJ-CEA alone, and their combination. In the non-definitive diagnosis group, cumulative PC incidence was compared between high and low PJ-CEA subgroups using Kaplan-Meier analysis.
resultsThe optimal PJ-CEA cutoff was 7.9 ng/mL (AUC 0.924). In the definitive diagnosis group, sensitivity increased from 51.2% with SPACE alone to 86.0% when combined with PJ-CEA (p < 0.001). In the non-definitive diagnosis group, elevated PJ-CEA (≥ 7.9 ng/mL) was associated with subsequent PC (HR 11.7, p = 0.025), with a higher cumulative incidence in the high PJ-CEA subgroup (p = 0.019). These findings are based on a limited number of events and should be interpreted as exploratory, requiring external validation.
conclusionsAfter excluding radiologically identifiable IPMN, PJ-CEA measurement during SPACE may improve diagnostic sensitivity for PC and may provide preliminary information for exploratory risk stratification in cytology-negative patients. Further external validation is required before PJ-CEA can be used to guide re-testing and surveillance strategies.
Indexed as
Identifiers
42406281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.